Drugs / MSC_Apceth
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT01351610 | Mar 2011 → Oct 2014 | limb ischemia, peripheral arterial disease | Apceth GmbH & Co. KG | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MSC_Apceth | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01351610 ↗ |
| Modality | Cell therapy | “autologous ex-vivo expanded non-hemapoietic bone-marrow derived stem cells” NCT01351610 ↗ |
| Route | Intravenous | “an intravenous infusion of Human Bone Marrow Derived Autologous, CD34-Negative Mesenchymal Stem Cells” NCT01351610 ↗ |